Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$0.16 - $281.7 $46,036 - $81.1 Million
-287,730 Reduced 63.1%
168,233 $28,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $306.0 $38,367 - $39.1 Million
-127,890 Reduced 21.9%
455,963 $137,000
Q2 2022

Aug 12, 2022

BUY
$0.38 - $1.14 $12,380 - $37,140
32,579 Added 5.91%
583,853 $243,000
Q1 2022

May 13, 2022

SELL
$0.94 - $1.6 $112,054 - $190,731
-119,207 Reduced 17.78%
551,274 $629,000
Q3 2021

Nov 12, 2021

BUY
$1.66 - $2.27 $73,743 - $100,842
44,424 Added 7.1%
670,481 $1.38 Million
Q2 2021

Aug 13, 2021

BUY
$1.68 - $2.79 $1.05 Million - $1.75 Million
626,057 New
626,057 $1.43 Million

Others Institutions Holding WINT

About WINDTREE THERAPEUTICS INC


  • Ticker WINT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,627,900
  • Market Cap $22.1M
  • Description
  • Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart ...
More about WINT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.